Found: 44
Select item for more details and to access through your institution.
Is there a case for the early use of bisphosphonates in smouldering myeloma and MGUS? (Bisphosphonates in SMM & MGUS)
- Published in:
- 2007
- By:
- Publication type:
- Journal Article
Is there a case for the early use of bisphosphonates in smouldering myeloma and MGUS? (Bisphosphonates in SMM & MGUS).
- Published in:
- 2007
- By:
- Publication type:
- Letter
The impact of biomarkers of malignancy (IMWG SLiM criteria) in myeloma in a real‐world population: Clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (ANZ MRDR).
- Published in:
- British Journal of Haematology, 2024, v. 205, n. 4, p. 1337, doi. 10.1111/bjh.19624
- By:
- Publication type:
- Article
The second revision of the International Staging System (R2‐ISS) stratifies progression‐free and overall survival in multiple myeloma: Real world data results in an Australian and New Zealand Population.
- Published in:
- British Journal of Haematology, 2023, v. 200, n. 2, p. e17, doi. 10.1111/bjh.18536
- By:
- Publication type:
- Article
Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR).
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 5, p. 830, doi. 10.1111/bjh.18324
- By:
- Publication type:
- Article
Sickle cell disease in Australia: a snapshot from the Australian Haemoglobinopathy Registry.
- Published in:
- Internal Medicine Journal, 2024, v. 54, n. 5, p. 764, doi. 10.1111/imj.16297
- By:
- Publication type:
- Article
Pregnancy and assisted reproductive technology use in Australian female transfusion‐dependent haemoglobinopathy patients: a 20‐year retrospective analysis.
- Published in:
- Internal Medicine Journal, 2024, v. 54, n. 2, p. 290, doi. 10.1111/imj.16169
- By:
- Publication type:
- Article
The importance of frailty assessment in multiple myeloma: a position statement from the Myeloma Scientific Advisory Group to Myeloma Australia.
- Published in:
- Internal Medicine Journal, 2023, v. 53, n. 5, p. 819, doi. 10.1111/imj.16049
- By:
- Publication type:
- Article
COVID‐19 vaccination in haematology patients: an Australian and New Zealand consensus position statement.
- Published in:
- Internal Medicine Journal, 2021, v. 51, n. 5, p. 763, doi. 10.1111/imj.15247
- By:
- Publication type:
- Article
Successful kidney transplantation in a patient with stable multiple myeloma.
- Published in:
- Internal Medicine Journal, 2020, v. 50, n. 4, p. 492, doi. 10.1111/imj.14790
- By:
- Publication type:
- Article
A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis.
- Published in:
- Internal Medicine Journal, 2017, v. 47, n. 3, p. 262, doi. 10.1111/imj.13341
- By:
- Publication type:
- Article
A single‐day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapies.
- Published in:
- European Journal of Haematology, 2024, v. 113, n. 4, p. 521, doi. 10.1111/ejh.14266
- By:
- Publication type:
- Article
Benign clinical phenotype of co‐inherited congenital dyserythropoietic anaemia type I and heterozygous haemoglobin Lepore.
- Published in:
- 2023
- By:
- Publication type:
- Case Study
CD300f epitopes are specific targets for acute myeloid leukemia with monocytic differentiation.
- Published in:
- Molecular Oncology, 2019, v. 13, n. 10, p. 2107, doi. 10.1002/1878-0261.12549
- By:
- Publication type:
- Article
Regulatory T Cells and Multiple Myeloma.
- Published in:
- Clinical Lymphoma & Myeloma, 2008, v. 8, n. 5, p. 283
- By:
- Publication type:
- Article
Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study).
- Published in:
- European Journal of Haematology, 2017, v. 98, n. 2, p. 97, doi. 10.1111/ejh.12793
- By:
- Publication type:
- Article
Serum Free Light Chain Kinetics Is Predictive of Renal Response in Myeloma Patients With Renal Impairment--An ALLG Trial of Carfilzomib-Dexamethasone Therapy in Frontline and Relapse.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 8, p. 543, doi. 10.1016/j.clml.2024.04.001
- By:
- Publication type:
- Article
P-116: The impact of SLiM criteria in myeloma in a real-life population: clinical characteristics, treatment and outcome from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S98, doi. 10.1016/S2152-2650(21)02243-6
- By:
- Publication type:
- Article
The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR).
- Published in:
- 2021
- By:
- Publication type:
- journal article
Patient Reported Outcome Measures in multiple myeloma: real-time rePorTing to improve care (My-PROMPT) - a pilot randomised controlled trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e340, doi. 10.1016/j.clml.2019.09.561
- By:
- Publication type:
- Article
Prolonged Immunosuppression in Relapsed, Refractory Multiple Myeloma Leading to Cerebral Toxoplasmosis and Progressive Multifocal Leukoencephalopathy.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Carfilzomib (K) in relapsed and refractory multiple myeloma (RRMM): frailty subgroup analysis from phase 3 ASPIRE and ENDEAVOR.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e266, doi. 10.1016/j.clml.2019.07.299
- By:
- Publication type:
- Article
Receiving four or less cycles of therapy predicts poor survival in newly diagnosed transplant ineligible patients with myeloma who are treated with bortezomib-based induction.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e233, doi. 10.1016/j.clml.2019.09.388
- By:
- Publication type:
- Article
Pacific Islanders with multiple myeloma are younger and have inferior survival when compared to other ethnicities: a study from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e213, doi. 10.1016/j.clml.2019.09.354
- By:
- Publication type:
- Article
Accumulation of CD69+ Terminal Effector CD8+ T cells occurs in the bone marrow of newly diagnosed Myeloma patients who lack protective clonal Vb expanded cytotoxic T cells.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e29, doi. 10.1016/j.clml.2019.09.043
- By:
- Publication type:
- Article
Carfilzomib (K) in Relapsed and Refractory Multiple Myeloma (RRMM): Frailty Subgroup Analysis from Phase 3 ASPIRE and ENDEAVOR.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S320, doi. 10.1016/j.clml.2019.07.299
- By:
- Publication type:
- Article
Correlative Analyses of Cytokine Release Syndrome and Neurological Events in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S251, doi. 10.1016/j.clml.2019.07.158
- By:
- Publication type:
- Article
Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Lenalidomide-related Progressive Multifocal Leukoencephalopathy: A Case Report and Review of Drug-related Cases in Multiple Myeloma.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Global Pivotal Phase 2 Trial of the CD19-Targeted Therapy CTL019 In Adult Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)—An Interim Analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S373, doi. 10.1016/j.clml.2017.07.213
- By:
- Publication type:
- Article
Daratumumab, Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in RRMM Based on Prior Lines and Treatment Exposure: POLLUX.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e116, doi. 10.1016/j.clml.2017.03.211
- By:
- Publication type:
- Article
Rates of Upfront Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM): A report from the MRDR.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e30, doi. 10.1016/j.clml.2017.03.052
- By:
- Publication type:
- Article
Maturing Data from the Australia and New Zealand Myeloma and Related Diseases Registry.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e105, doi. 10.1016/j.clml.2017.03.190
- By:
- Publication type:
- Article
Depth of Response and MRD with Daratumumab Plus Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in RRMM: POLLUX.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e17, doi. 10.1016/j.clml.2017.03.029
- By:
- Publication type:
- Article
The T Cell in Myeloma.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX.
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 11, p. 1, doi. 10.1038/s41408-020-00375-2
- By:
- Publication type:
- Article
Patient‐reported outcome measures in multiple myeloma: Real‐time reporting to improve care (My‐PROMPT) ‐ a pilot randomized controlled trial.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 7, p. E178, doi. 10.1002/ajh.25815
- By:
- Publication type:
- Article
Transformation and progression of Waldenström's macroglobulinemia following cladribine therapy in two cases: natural evolution or iatrogenic causation?
- Published in:
- American Journal of Hematology, 2006, v. 81, n. 2, p. 110, doi. 10.1002/ajh.20475
- By:
- Publication type:
- Article
Either interleukin-12 or interferon-γ can correct the dendritic cell defect induced by transforming growth factor β<sub>1</sub> in patients with myeloma.
- Published in:
- British Journal of Haematology, 2004, v. 125, n. 6, p. 743, doi. 10.1111/j.1365-2141.2004.04984.x
- By:
- Publication type:
- Article
A CD2 high-expressing stress-resistant human plasmacytoid dendritic-cell subset.
- Published in:
- Immunology & Cell Biology, 2016, v. 94, n. 5, p. 447, doi. 10.1038/icb.2015.116
- By:
- Publication type:
- Article
Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Variation in immunoglobulin use and impact on survival in myeloma.
- Published in:
- EJHaem, 2024, v. 5, n. 4, p. 690, doi. 10.1002/jha2.938
- By:
- Publication type:
- Article
An in vitro system for expression analysis of mutations of the β-globin gene: validation and application to two mutations in the 5′ UTR.
- Published in:
- British Journal of Haematology, 1999, v. 106, n. 4, p. 938, doi. 10.1046/j.1365-2141.1999.01659.x
- By:
- Publication type:
- Article